# Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

> **NCT04902040** · PHASE1,PHASE2 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 19 (actual)

## Conditions studied

- Advanced Bladder Carcinoma
- Advanced Lung Non-Small Cell Carcinoma
- Advanced Malignant Solid Neoplasm
- Advanced Melanoma
- Advanced Merkel Cell Carcinoma
- Advanced Renal Cell Carcinoma
- Clinical Stage III Cutaneous Melanoma AJCC v8
- Clinical Stage III Merkel Cell Carcinoma AJCC v8
- Clinical Stage IV Cutaneous Melanoma AJCC v8
- Clinical Stage IV Merkel Cell Carcinoma AJCC v8
- Pathologic Stage III Cutaneous Melanoma AJCC v8
- Pathologic Stage III Merkel Cell Carcinoma AJCC v8
- Pathologic Stage IIIA Cutaneous Melanoma AJCC v8
- Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8
- Pathologic Stage IIIB Cutaneous Melanoma AJCC v8
- Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8
- Pathologic Stage IIIC Cutaneous Melanoma AJCC v8
- Pathologic Stage IIID Cutaneous Melanoma AJCC v8
- Pathologic Stage IV Cutaneous Melanoma AJCC v8
- Pathologic Stage IV Merkel Cell Carcinoma AJCC v8
- Stage III Bladder Cancer AJCC v8
- Stage III Lung Cancer AJCC v8
- Stage III Renal Cell Cancer AJCC v8
- Stage IIIA Bladder Cancer AJCC v8
- Stage IIIA Lung Cancer AJCC v8
- Stage IIIB Bladder Cancer AJCC v8
- Stage IIIB Lung Cancer AJCC v8
- Stage IIIC Lung Cancer AJCC v8
- Stage IV Bladder Cancer AJCC v8
- Stage IV Lung Cancer AJCC v8
- Stage IV Renal Cell Cancer AJCC v8
- Stage IVA Bladder Cancer AJCC v8
- Stage IVA Lung Cancer AJCC v8
- Stage IVB Bladder Cancer AJCC v8
- Stage IVB Lung Cancer AJCC v8

## Interventions

- **BIOLOGICAL:** Atezolizumab
- **DRUG:** Avelumab
- **BIOLOGICAL:** Durvalumab
- **BIOLOGICAL:** Nivolumab
- **BIOLOGICAL:** Pembrolizumab
- **DRUG:** Plinabulin
- **RADIATION:** Radiation Therapy

## Key facts

- **NCT ID:** NCT04902040
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-04-14
- **Primary completion:** 2025-02-27
- **Final completion:** 2025-02-27
- **Target enrollment:** 19 (ACTUAL)
- **Why stopped:** PI requested.
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04902040

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04902040, "Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04902040. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*